Search
Toggle theme
Menu
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial | NobleBlocks
Back
Home
Publications
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
Public
More options
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial
N
Shared by
NobleBlocks
on May 1, 2021 • 12:00 AM UTC
Authors:
Corinne Faivre-Finn
,
David Vicente
,
Takayasu Kurata
+20 more
Download PDF
Share
Summary
Sum
PDF
Figures
Figs
Discrepancies
Disc
EDDII
Article
Art
Finding related papers...
Discussions
(0)
Add Comment
No comments yet
Be the first to share your thoughts!
